Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mind Medicine Mindmed Inc (MMEDF)

Mind Medicine Mindmed Inc (MMEDF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

NEW YORK , Aug. 14, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results...

MMEDF : 0.3818 (+1.81%)
MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

BASEL, Switzerland , Aug. 13, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its presence in Europe . The leading neuro-pharmaceutical company for psychedelic...

MMEDF : 0.3818 (+1.81%)
Venture Company Investor Presentations Now Available for On-Demand Viewing

NEW YORK , Aug. 10, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the August 6 th OTCQB...

BIGG : 0.0003 (unch)
VYGR : 11.29 (+0.89%)
IDEX : 1.3200 (-7.04%)
AMMX : 0.0108 (+3.85%)
BBKCF : 0.1157 (-14.11%)
BFGC : 0.1615 (-2.12%)
DFLYF : 0.4501 (-0.55%)
GRBX : 0.1570 (-4.85%)
HLYK : 0.1550 (+19.23%)
IDXAF : 0.1800 (unch)
LLKKF : 0.0300 (+14.94%)
MMEDF : 0.3818 (+1.81%)
NEXCF : 4.4066 (+6.18%)
PDPTF : 1.6650 (-4.86%)
ROIUF : 0.4150 (-11.38%)
SEGN : 0.1500 (-16.62%)
VRSSF : 0.1770 (+1.90%)
VYGVF : 0.7000 (-2.40%)
ROI.VN : 0.600 (+1.69%)
MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Applauds Health Canada's Approval Of Psilocybin Compassionate Access For Patients

MMEDF : 0.3818 (+1.81%)
Live Investor Conference & Webinar: Venture Companies Present August 6th

NEW YORK , Aug. 3, 2020 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming OTCQB Venture Virtual lnvestor Conference, the leading proprietary investor conference...

BIGG : 0.0003 (unch)
VYGR : 11.29 (+0.89%)
IDEX : 1.3200 (-7.04%)
ROI.VN : 0.600 (+1.69%)
AMMX : 0.0108 (+3.85%)
BBKCF : 0.1157 (-14.11%)
BFGC : 0.1615 (-2.12%)
DFLYF : 0.4501 (-0.55%)
GRBX : 0.1570 (-4.85%)
HLYK : 0.1550 (+19.23%)
IDXAF : 0.1800 (unch)
LLKKF : 0.0300 (+14.94%)
MMEDF : 0.3818 (+1.81%)
NEXCF : 4.4066 (+6.18%)
PDPTF : 1.6650 (-4.86%)
ROIUF : 0.4150 (-11.38%)
SEGN : 0.1500 (-16.62%)
VRSSF : 0.1770 (+1.90%)
VYGVF : 0.7000 (-2.40%)
MindMed Completes Dosing 18-MC Phase 1 Study

NEW YORK , July 28, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending...

MMEDF : 0.3818 (+1.81%)
Reports Indicate Psychedelic Medicine Could be Better Investing Opportunity Than Cannabis

, /PRNewswire/ -- Over the last few years, all the talk has been about cannabis, cannabis… cannabis. CBD, CBG, THC and so on… but recent reports see the spotlight moving onto a different new "old"...

PSYC : 0.0100 (-5.66%)
SHRMF : 0.4700 (-2.08%)
SHRM.CN : 0.890 (+3.49%)
BOSQF : 0.0756 (+8.00%)
BOSS.CN : 0.095 (unch)
MMEDF : 0.3818 (+1.81%)
PEMTF : 0.1286 (+0.31%)
MOTA.CN : 0.165 (-2.94%)
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EDT

MMEDF : 0.3818 (+1.81%)
Psychedelic Medicine Stocks Garner Serious Investor Interest

, /PRNewswire/ -- Investor interest in alternative psychedelic medicine is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either...

PYPL : 193.07 (+0.91%)
PFE : 38.17 (-0.42%)
MYCO.CN : 0.520 (-1.89%)
NLBIF : 0.6150 (-6.82%)
NFLX : 481.33 (+1.23%)
MMEDF : 0.3818 (+1.81%)
Psychedelic Drugs Market Projected to Reach $6.85 Billion by 2027

, /PRNewswire/ -- The psychedelic drugs market is projected to grow at a CAGR of 16.3% over the next eight years to , according to Data Bridge Market Research. The key factors that will fuel this growth...

AGN : 193.02 (+0.02%)
JNJ : 148.00 (-1.11%)
NUMI.VN : 0.260 (-3.70%)
LKYSD : 0.3330 (+17.54%)
PEMTF : 0.1286 (+0.31%)
MOTA.CN : 0.165 (-2.94%)
ABBV : 94.68 (-0.87%)
MMEDF : 0.3818 (+1.81%)
MindMed Developing IP For Personalized Psychedelic Assisted Therapies

MindMed, in collaboration with the University Hospital Basel, has filed two separate patent applications for technologies to screen and optimize the dosing of MDMA and LSD

MMEDF : 0.3818 (+1.81%)
BGHM : 0.4600 (+12.20%)
Rising Anxiety & Mental Health Issues are a Growing Concern as People Continue to Work From Home

, /PRNewswire/ -- As pandemic-related social distancing measures continue, employers across the globe are extending work from home orders. (NASDAQ:MSFT) is until October, while tech giants like Google...

ZOOM : 10.4000 (+23.81%)
LLY : 150.46 (-1.37%)
FB : 261.30 (+0.54%)
MSFT : 208.70 (-0.23%)
MMEDF : 0.3818 (+1.81%)
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials

MMEDF : 0.3818 (+1.81%)
Recent Studies Indicating CBD may be Better Therapy for Treating Anxiety Than Medical Marijuana

, /PRNewswire/ -- Researchers have been looking at more and more uses for medical marijuana in recent years. Marijuana can affect the body in many ways beyond just getting the user high. The high feeling...

SHRMF : 0.4700 (-2.08%)
SHRM.CN : 0.890 (+3.49%)
RTSL : 1.0000 (-28.57%)
CGC : 17.32 (+0.41%)
WEED.TO : 22.89 (-0.04%)
OGI : 1.3900 (+2.96%)
OGI.TO : 1.84 (+3.37%)
MMEDF : 0.3818 (+1.81%)
Psychedelic-derived Therapies are Just What the Doctor Ordered to Address a Historic Mental Illness Epidemic

, /PRNewswire/ -- While the global death toll caused by the pandemic is well-publicized, a lesser-known side effect of the ongoing pandemic is the rise in mental illness that it has generated. Due to...

SEEL : 1.0600 (unch)
SHRM.CN : 0.890 (+3.49%)
SHRMF : 0.4700 (-2.08%)
NUMI.VN : 0.260 (-3.70%)
LKYSD : 0.3330 (+17.54%)
JNJ : 148.00 (-1.11%)
MMEDF : 0.3818 (+1.81%)
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients

MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel's Liechti Lab

MMEDF : 0.3818 (+1.81%)
BGHM : 0.4600 (+12.20%)
Psychedelic Medicine and the Future of Mental Health Care Looks Promising

, /PRNewswire/ -- After decades of having a bad rep, psychedelics are making their way back into the medical world and are being touted for For years, Big Pharma companies (NYSE:PFE), (NYSE:TAK),(NYSE:TEVA)...

TKPYY : 16.5900 (-0.90%)
TAK : 18.55 (-0.75%)
ABBV : 94.68 (-0.87%)
TEVA : 11.57 (-0.60%)
PFE : 38.17 (-0.42%)
MMEDF : 0.3818 (+1.81%)
Psychedelic Drugs Market Projected to Reach $6,859.95 Million by 2027

, /PRNewswire/ -- The psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. analyses that the market is growing with a CAGR of 16.3% in the forecast period...

PSYC : 0.0100 (-5.66%)
SHRM.CN : 0.890 (+3.49%)
BOSS.CN : 0.095 (unch)
MOTA.CN : 0.165 (-2.94%)
SHRMF : 0.4700 (-2.08%)
BOSQF : 0.0756 (+8.00%)
MMEDF : 0.3818 (+1.81%)
PEMTF : 0.1286 (+0.31%)
Psychedelic Drugs Could Potentially Treat Impending Post-lockdown Mental Health Epidemic

, /PRNewswire/ --  Trials are already underway testing the use of psychedelics such as psilocybin, LSD, ketamine, ecstasy and other currently scheduled drugs to predicted to hit after the lockdown...

JNJ : 148.00 (-1.11%)
SHRM.CN : 0.890 (+3.49%)
SHRMF : 0.4700 (-2.08%)
LLY : 150.46 (-1.37%)
NUMI.VN : 0.260 (-3.70%)
LKYSD : 0.3330 (+17.54%)
MMEDF : 0.3818 (+1.81%)
BGHM : 0.4600 (+12.20%)
MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

BASEL, Switzerland , June 2, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the...

MMEDF : 0.3818 (+1.81%)

Van Meerten Stock Picks

The 5 Best MidCaps
I wanted to find the 5 Mid Caps that have had the best momentum over the past year so I used Barchart to sort the S&P 400 MidCap Stock Index for the stocks with the highest Weighted Alpha and technical buying signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar